Withdraw mifepristone approval and restore pre-2016/2021 REMS and mail bans
Mandate directs FDA to reverse chemical abortion drug approval, restore REMS/in-person dispensing, reinstate earlier protocols, stop mail-order distribution under federal mailing statutes, and tighten FAERS reporting.
Mandate
Mandate Ch. 14 (HHS) — FDA Abortion Pills / Mail-Order Abortions: reverse approval of chemical abortion drugs; as interim step restore REMS removing tele-abortion/mail distribution; reinstate earlier Mifeprex safety protocols (gestational limits, in-person dispensing, adverse-event reporting); stop promoting mail-order abortions in violation of federal mailing laws; strengthen FAERS and inspection transparency.
Undo plan
1) Rescind any FDA withdrawal or reimposed REMS that eliminate evidence-based access to mifepristone/misoprostol under labeled conditions.
2) Restore current scientific labeling process with transparent advisory committees and REMS tailored to safety data, not ideology.
3) Clarify DOJ/FDA positions on mailing statutes consistent with court precedent and patient access.
4) Improve FAERS usability for ER adverse-event reporting without chilling lawful care.
5) Verify: Federal Register notices; advisory-committee dockets; access metrics by gestation and geography.